Logan Capital Management Inc. Increases Position in Sanofi $SNY

Logan Capital Management Inc. lifted its holdings in Sanofi (NASDAQ:SNY) by 10.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 147,363 shares of the company’s stock after buying an additional 14,376 shares during the period. Logan Capital Management Inc.’s holdings in Sanofi were worth $7,141,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Flagship Harbor Advisors LLC purchased a new position in shares of Sanofi in the 4th quarter worth approximately $25,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Sanofi in the 3rd quarter worth approximately $29,000. Palisade Asset Management LLC purchased a new position in shares of Sanofi in the 3rd quarter worth approximately $30,000. Annis Gardner Whiting Capital Advisors LLC boosted its stake in shares of Sanofi by 544.4% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock worth $34,000 after buying an additional 588 shares during the last quarter. Finally, Larson Financial Group LLC boosted its stake in shares of Sanofi by 48.9% in the 4th quarter. Larson Financial Group LLC now owns 810 shares of the company’s stock worth $39,000 after buying an additional 266 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Trading Up 1.2%

NASDAQ:SNY opened at $44.11 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $106.94 billion, a PE ratio of 12.32, a price-to-earnings-growth ratio of 1.07 and a beta of 0.34. The firm’s 50 day moving average is $45.21 and its 200 day moving average is $46.56. Sanofi has a 12 month low of $42.28 and a 12 month high of $52.68.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were issued a dividend of $2.4225 per share. This represents a yield of 559.0%. The ex-dividend date of this dividend was Monday, May 4th. This is a positive change from Sanofi’s previous annual dividend of $2.04. Sanofi’s payout ratio is presently 49.16%.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of research reports. Morgan Stanley set a $52.00 price target on shares of Sanofi in a report on Friday, May 1st. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a report on Monday, April 20th. Argus raised shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Finally, Bank of America cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $51.00.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.